Estrogen Therapy Contraindications in Patients with Cerebrovascular History

Introduction to Contraindications

The American Heart Association and American Stroke Association state that postmenopausal hormone therapy is not recommended for women who have had ischemic stroke or TIA, with a Class III recommendation and Level of Evidence A 1.

The Women's Estrogen for Stroke Trial demonstrated that women with prior stroke or TIA who received estradiol had a higher risk of fatal stroke and worse functional outcomes after recurrent strokes compared to placebo 1.
High-quality evidence from the Women's Health Initiative showed that menopausal hormone therapy was associated with increased risk for cerebrovascular accidents and venous thromboembolic events 2, 3.
The American College of Cardiology reinforces that HRT should not be initiated for any indication in women with a history of cardiovascular events, including TIA, as the cardiovascular and cerebrovascular risks supersede any potential benefits 1.

Combined oral contraceptives in women with pre-existing vascular risk factors show dramatically elevated risks: myocardial infarction OR 25 in women with dyslipidemia and OR 6 to 68 in women with hypertension 4.
Estrogen-containing contraceptives in women with migraine show ischemic stroke OR 2.08 to 16.9, demonstrating the amplified cerebrovascular risk in susceptible populations 4.

Bisphosphonates, denosumab, or teriparatide should be used as first-line therapy for osteoporosis in patients with a history of TIA 2, 3.
Bisphosphonates reduce vertebral, nonvertebral, and hip fractures without the cerebrovascular risks of estrogen 2.
Denosumab reduces vertebral, nonvertebral, and hip fractures and is particularly effective in young women with hypogonadism 2.
Teriparatide reduces vertebral and nonvertebral fractures and is especially useful in severe osteoporosis, though it carries risks of hypercalcemia and upper GI symptoms 2, 3.

Initiate bisphosphonate therapy as first-line treatment for osteoporosis, with adequate calcium and vitamin D supplementation to support bone health 2, 3.
Consider denosumab if bisphosphonates are contraindicated or not tolerated 2.
Reserve teriparatide for severe osteoporosis with very high fracture risk or failure of other therapies 2, 3.
Monitor bone mineral density with DEXA scans every 1-2 years to assess treatment response 2.
Address the underlying hypogonadism through non-estrogen mechanisms if possible, though bone protection must come from the agents listed above rather than hormone replacement 1.